{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:32:22Z","timestamp":1793424742682,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-025-04463-4","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:59:02Z","timestamp":1762419542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["One-year clinical outcomes of four-dose induction versus immediate treat-and-extend faricimab regimens in pretreated neovascular age-related macular degeneration"],"prefix":"10.1186","volume":"25","author":[{"given":"Moreno","family":"Menghini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas M.","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin K.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"issue":"1","key":"4463_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000003003","volume":"41","author":"JS Heier","year":"2021","unstructured":"Heier JS, Singh RP, Wykoff CC, Csaky KG, Lai TYY, Loewenstein A. The angiopoietin\/tie pathway in retinal vascular diseases: a review. Retina. 2021;41(1):1\u201319.","journal-title":"Retina"},{"key":"4463_CR2","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.2147\/OPTH.S231801","volume":"15","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Russell MW, Aziz AA, Danzig CJ, Weng CY, Eichenbaum DA. Angiopoietins as potential targets in management of retinal disease. Clin Ophthalmol. 2021;15:3747\u201355.","journal-title":"Clin Ophthalmol"},{"issue":"10326","key":"4463_CR3","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"issue":"8","key":"4463_CR4","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R. Tenaya and lucerne. Ophthalmology. 2024;131(8):914\u201326.","journal-title":"Ophthalmology"},{"issue":"2","key":"4463_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/life14020193","volume":"14","author":"B Ng","year":"2024","unstructured":"Ng B, Kolli H, Ajith Kumar N, Azzopardi M, Logeswaran A, Buensalido J. Real-World data on faricimab switching in Treatment-Refractory neovascular Age-Related macular degeneration. Life. 2024;14(2):193.","journal-title":"Life"},{"issue":"6","key":"4463_CR6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.oret.2023.11.015","volume":"8","author":"R Raimondi","year":"2024","unstructured":"Raimondi R, Falfeli T, Bogdanova-Bennet A, Varma D, Habib M, Kotagiri A. Outcomes of Treatment-Resistant neovascular Age-Related macular degeneration switched from Aflibercept to faricimab. Ophthalmol Retina. 2024;8(6):537\u201344.","journal-title":"Ophthalmol Retina"},{"key":"4463_CR7","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.2147\/OPTH.S532179","volume":"19","author":"K Robinson","year":"2025","unstructured":"Robinson K, Cooper SJ, Persaud S, Frederick JL, Singh RP. Discordance among patients and ophthalmologists regarding the burden of intravitreal injections. Clin Ophthalmol. 2025;19:2637\u201345.","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"4463_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, Waheed NK, Chakravarthy U, Rosenfeld PJ, Holz FG, et al. Consensus nomenclature for reporting neovascular Age-Related macular degeneration data: consensus on neovascular Age-Related macular degeneration nomenclature study group. Ophthalmology. 2020;127(5):616\u201336.","journal-title":"Ophthalmology"},{"issue":"4","key":"4463_CR9","doi-asserted-by":"publisher","first-page":"e34823","DOI":"10.1371\/journal.pone.0034823","volume":"7","author":"P Tewarie","year":"2012","unstructured":"Tewarie P, Balk L, Costello F, Green A, Martin R, Schippling S, Petzold A. The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS ONE. 2012;7(4):e34823.","journal-title":"PLoS ONE"},{"issue":"4","key":"4463_CR10","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00417-023-06319-3","volume":"262","author":"G Grimaldi","year":"2024","unstructured":"Grimaldi G, Cancian G, Rizzato A, Casanova A, Perruchoud-Ader K, Clerici M. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study. Graefes Arch Clin Exp Ophthalmol. 2024;262(4):1151\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4463_CR11","first-page":"1","volume":"2024","author":"H Kamao","year":"2024","unstructured":"Kamao H, Mitsui E, Date Y, Goto K, Mizukawa K, Miki A. The effect of a loading dose regimen in the switch to Brolucizumab for patients with Aflibercept-Resistant nAMD. Grigoropoulos V Editor. 2024;2024:1\u20136.","journal-title":"Grigoropoulos V Editor"},{"issue":"6","key":"4463_CR12","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s10384-023-01024-4","volume":"67","author":"T Hikichi","year":"2023","unstructured":"Hikichi T. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration. Jpn J Ophthalmol. 2023;67(6):652\u20136.","journal-title":"Jpn J Ophthalmol"},{"issue":"15","key":"4463_CR13","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.3390\/jcm12155145","volume":"12","author":"M Kishi","year":"2023","unstructured":"Kishi M, Miki A, Kamimura A, Okuda M, Matsumiya W, Imai H. Short-Term outcomes of faricimab treatment in Aflibercept-Refractory eyes with neovascular Age-Related macular degeneration. J Clin Med. 2023;12(15):5145.","journal-title":"J Clin Med"},{"issue":"4","key":"4463_CR14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3390\/life14040476","volume":"14","author":"A Machida","year":"2024","unstructured":"Machida A, Oishi A, Ikeda J, Kurihara J, Yoneda A, Tsuiki E. Factors associated with success of switching to faricimab for neovascular Age-Related macular degeneration refractory to intravitreal Aflibercept. Life. 2024;14(4):476.","journal-title":"Life"},{"issue":"1","key":"4463_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","volume":"8","author":"A Szigiato","year":"2024","unstructured":"Szigiato A, Mohan N, Talcott KE, Mammo DA, Babiuch AS, Kaiser PK. Short-Term outcomes of faricimab in patients with neovascular Age-Related macular degeneration on prior Anti-VEGF therapy. Ophthalmol Retina. 2024;8(1):10\u20137.","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"4463_CR16","doi-asserted-by":"publisher","first-page":"9087","DOI":"10.1038\/s41598-024-59894-8","volume":"14","author":"H Takahashi","year":"2024","unstructured":"Takahashi H, Inoda S, Takahashi H, Takahashi R, Hashimoto Y, Yoshida H. One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior Brolucizumab treatment. Sci Rep. 2024;14(1):9087.","journal-title":"Sci Rep"},{"key":"4463_CR17","doi-asserted-by":"crossref","unstructured":"Giancipoli E, Guglielmi A, Bux AV, Clima GME, Pignatelli F, Boscia F. Real-world outcomes of a loading phase with intravitreal faricimab in neovascular age-related macular degeneration (n-AMD) and diabetic macular edema (DME). Ophthalmol Ther. 2024.","DOI":"10.1007\/s40123-024-00980-5"},{"issue":"1","key":"4463_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","volume":"262","author":"K Kataoka","year":"2024","unstructured":"Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M. Six-month outcomes of switching from Aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262(1):43\u201351.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4463_CR19","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2147\/OPTH.S409822","volume":"17","author":"EH Leung","year":"2023","unstructured":"Leung EH, Oh DJ, Alderson SE, Bracy J, McLeod M, Perez LI. Initial Real-World experience with faricimab in Treatment-Resistant neovascular Age-Related macular degeneration. Clin Ophthalmol. 2023;17:1287\u201393.","journal-title":"Clin Ophthalmol"},{"key":"4463_CR20","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2147\/OPTH.S463624","volume":"18","author":"N Quah","year":"2024","unstructured":"Quah N, Javed K, Arbi L, Hanumunthadu D. Real-World outcomes of faricimab treatment for neovascular Age-Related macular degeneration and diabetic macular edema. Clin Ophthalmol. 2024;18:1479\u201390.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"4463_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10792-024-03297-1","volume":"44","author":"AA Aldhanhani","year":"2024","unstructured":"Aldhanhani AA, Azzam OA, AlAli SH, Almasri KG, Aljneibi SH, Pichi F. Switch to faricimab after initial treatment with Aflibercept in eyes with neovascular age-related macular degeneration. Int Ophthalmol. 2024;44(1):369.","journal-title":"Int Ophthalmol"},{"issue":"1","key":"4463_CR22","doi-asserted-by":"publisher","first-page":"9600","DOI":"10.1038\/s41598-024-59632-0","volume":"14","author":"F Eckardt","year":"2024","unstructured":"Eckardt F, Lorger A, Hafner M, Klaas JE, Schworm B, Kreutzer TC. Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration. Sci Rep. 2024;14(1):9600.","journal-title":"Sci Rep"},{"key":"4463_CR23","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/OPTH.S424315","volume":"17","author":"RB Rush","year":"2023","unstructured":"Rush RB. One-Year outcomes of faricimab treatment for Aflibercept-Resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:2201\u20138.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"4463_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40942-024-00525-9","volume":"10","author":"FM Penha","year":"2024","unstructured":"Penha FM, Masud M, Khanani ZA, Thomas M, Fong RD, Smith K. Review of real-world evidence of dual Inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retina Vitr. 2024;10(1):5.","journal-title":"Int J Retina Vitr"},{"key":"4463_CR25","unstructured":"APMOC B: BNSSG Recommended Commissioning Pathway. 2024. https:\/\/www.remedybnssgicbnhsuk\/media\/0omh41xf\/bnssg-namd-pathway-final-april-2024pdf."}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04463-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04463-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04463-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:59:06Z","timestamp":1762419546000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-025-04463-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4463"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04463-4","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"13 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the relevant Ethics Committees (Ethikkommission Nordwest- und Zentralschweiz (EKNZ) 2024\u2009\u2212\u200900243 and Comitato etico cantonale Ticino (CECT) 2023\u2009\u2212\u200900653). All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"MM provided consulting and\/or speaker services for Abbvie, Apellis, Bayer, Novartis, Roche, and he is consultant and holds equity of Endogena Inc. GG provided consulting and\/or speaker services for Abbvie, Apellis, Bayer and Roche.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"624"}}